Cargando…

Efficacy and Safety of Anti-Tumor Necrosis Factor-Alpha Agents for Patients with Intestinal Behcet’s Disease: A Systematic Review and Meta-Analysis

PURPOSE: Intestinal Behcet’s disease (BD) is a systemic autoimmune disease for which treatment options are limited. As a prospective therapeutic strategy for intestinal BD, anti-tumor necrosis factor-alpha (anti-TNF-α) agents have received increasing attention. In this study, we conducted a systemat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Qingfeng, Ma, Chunyan, Dong, Rongrong, Xiang, Weizhen, Li, Meiqi, Ma, Zhenzhen, Yang, Qingrui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819411/ https://www.ncbi.nlm.nih.gov/pubmed/35083900 http://dx.doi.org/10.3349/ymj.2022.63.2.148

Ejemplares similares

The Role of Anti-U1 RNP Antibody in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis
por: Xiang, Weizhen, et al.
Publicado: (2022)

Distribution and clinical significance of anti-carbamylation protein antibodies in rheumatological diseases among the Chinese Han population
por: Dong, Rongrong, et al.
Publicado: (2023)

Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet’s Disease
por: Park, Jihye, et al.
Publicado: (2018)

Risk Factors for Surgery in Patients with Intestinal Behçet’s Disease During Anti-Tumor Necrosis Factor-Alpha Therapy
por: Han, So Jung, et al.
Publicado: (2023)

Effectiveness and Safety of Anti-Tumor Necrosis Factor-Alpha Agents Treatment in Behcets’ Disease-Associated Uveitis: A Systematic Review and Meta-Analysis
por: Hu, Yunwei, et al.
Publicado: (2020)

Efficacy and predictor of anti-TNFα agents in patients with intestinal Behçet's disease
por: Miyazaki, Haruka, et al.
Publicado: (2022)

Efficacy of Anti-Tumor Necrosis Factor-α Therapy Against Intestinal Behçet’s Disease Complicated by Recurrent Enterocutaneous Fistulae
por: Kashima, Hitomi, et al.
Publicado: (2022)

Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor α monoclonal antibody (Infliximab)
por: Lee, Jung Hoon, et al.
Publicado: (2007)

Role of CXCL16 in BLM-induced epithelial–mesenchymal transition in human A549 cells
por: Ma, Zhenzhen, et al.
Publicado: (2021)

Anti-tumour necrosis factor-alpha agent therapy, compared with conventional therapy, reduces the relapse of uveitis in patients with behçet’s disease: A systematic review of controlled trials
por: Zhou, Xinwei, et al.
Publicado: (2022)

Predictors of rapidly progressive interstitial lung disease and prognosis in Chinese patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis
por: Li, Meiqi, et al.
Publicado: (2023)

TNF and anti-TNF agents in Behçet's disease
por: Calamia, KT
Publicado: (2003)

Anti-TNF-α agents for refractory intestinal Behçet’s disease: case series and meta-analysis
por: Zhan, Shukai, et al.
Publicado: (2022)

Neutrophil extracellular traps and pulmonary fibrosis: an update
por: Yan, Suyan, et al.
Publicado: (2023)

Efficacy of iron supplementation in patients with inflammatory bowel disease treated with anti-tumor necrosis factor-alpha agents
por: Kim, Su Young, et al.
Publicado: (2020)

Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease: A Multicenter, Phase 3 Study (BEGIN)
por: Cheon, Jae Hee, et al.
Publicado: (2023)

Efficacy of Adalimumab in a Girl with Refractory Intestinal Behcet's Disease
por: Kaji, Mariko, et al.
Publicado: (2015)

Efficacy of Calcineurin Inhibitors for Induction of Remission in Intestinal Behçet’s Disease
por: Kawaguchi, Takaaki, et al.
Publicado: (2022)

Clinical manifestations and anti-TNF alpha therapy of juvenile Behçet’s disease in Taiwan
por: Hu, Ya-Chiao, et al.
Publicado: (2019)

Intestinal Perforations in Behçet’s Disease
por: Chou, Shao-Jiun, et al.
Publicado: (2007)

Clinical heterogeneity of ocular Behçet’s syndrome versus intestinal Behçet’s syndrome: a cross-sectional study from Shanghai Behçet’s syndrome database
por: Hou, Cheng-cheng, et al.
Publicado: (2022)

Intestinal Behcet’s Disease: A Review of the Immune Mechanism and Present and Potential Biological Agents
por: He, Kun, et al.
Publicado: (2023)

Anti-tubulin-alpha-1c antibody as a marker of value in Behçet syndrome
por: Amin, Mariam Maged, et al.
Publicado: (2022)

Systemic use of tumor necrosis factor alpha as an anticancer agent
por: Roberts, Nicholas J., et al.
Publicado: (2011)

The use of anti-interleukin-1 agents and tumor necrosis factor‐alpha inhibitors in renal transplant recipients
por: Yazısız, Veli, et al.
Publicado: (2021)

Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
por: Eriksson, Carl, et al.
Publicado: (2023)

Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report
por: Gulli, Salvatore, et al.
Publicado: (2003)

Diagnosis and management of intestinal Behçet’s disease
por: Hisamatsu, Tadakazu, et al.
Publicado: (2014)

Outcome Predictors for Intestinal Behçet's Disease
por: Park, Jae Jun, et al.
Publicado: (2013)

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety
por: Alonso-Ruiz, Alberto, et al.
Publicado: (2008)

A metagenomic study of the gut microbiome in Behcet’s disease
por: Ye, Zi, et al.
Publicado: (2018)

The Efficacy of Anti-Tumor Necrosis Factor Alpha for Symptomatic Stricturing Small Bowel Crohn’s Disease
por: Alourfi, Mansour, et al.
Publicado: (2020)

Inhibition of Th17 differentiation by anti-TNF-alpha therapy in uveitis patients with Behçet's disease
por: Sugita, Sunao, et al.
Publicado: (2012)

Rare and Serious Adverse Effects of Anti-Tumor Necrosis Factor-Alpha (TNF-α) Agents in Crohn’s Disease
por: Kim, Sun, et al.
Publicado: (2021)

De-Escalation of Anti-Tumor Necrosis Factor Alpha Agents and Reduction in Adverse Effects: A Systematic Review
por: Bouhuys, Marleen, et al.
Publicado: (2022)

Tumour Necrosis Factor Alpha in Intestinal Homeostasis and Gut Related Diseases
por: Ruder, Barbara, et al.
Publicado: (2019)

The Efficacy of Medium- to Long-term Anti-TNF-α Antibody-based Maintenance Therapy in Behçet's Disease Patients with Intestinal Lesions
por: Kambayashi, Harutaka, et al.
Publicado: (2020)

Long-Term Efficacy of Adalimumab in Patients With Intestinal Behcet’s Disease: Eight Consecutive Cases
por: Tanida, Satoshi, et al.
Publicado: (2016)

Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis
por: Bergman, Martin J., et al.
Publicado: (2014)

Updated treatment strategies for intestinal Behçet’s disease
por: Park, Yong Eun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kt1c6kndbr6a8gpntbckv75ebg